Key facts
- It has raised $27.0M; the latest was Later Stage VC ($9.3M) in Apr 2026.
- Notable investors include Tech Incubator Program for Startup, Smilegate Investment, BonAngels Venture Partners, DAYLI Partners, Hana Securities — 23 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 23 names
- ·Watchlist + deal alerts for SN BioScience
- ·The full record, as it builds
Funding rounds
No funding rounds for SN BioScience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SN BioScience
Developer of a nano-medicine drug delivery system designed for cancer therapeutics. The company's system utilizes physico chemically ingrated pharmaco metric technology and is related to the physicochemical properties of the drug, the mechanism of delivery, and the indication, enabling clients to improve clinical outcomes.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2017
- Employees
- 25
- Website
- snbioscience.com/
- Ownership
- Privately Held (backing)
SN BioScience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SN BioScience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SN BioScience in its N-PORT filings yet. We sweep new filings monthly.